Best Options Strategy for NBP
Looking for the best options strategy for NovaBridge Biosciences (NBP)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live NBP option chain right now, and a simple map from your view on NBP to the strategy that fits it. Model any of them in the calculator before you trade.
About NBP
NovaBridge Biosciences (NBP) is a major company in Biotechnology. Options traders on NBP tend to watch , since these can drive large moves in the share price.
About NovaBridge Biosciences
NovaBridge Biosciences is a biotech company focused on developing immunotherapy drugs, primarily targeting cancer through bispecific antibodies and related biologics. The company operates two main business areas: oncology and ophthalmology. In oncology, its lead program is givastomig, a CLDN18.2-targeting bispecific antibody currently in phase 2 testing for gastric cancer and other gastrointestinal tumors when combined with checkpoint inhibitors and chemotherapy. The pipeline also includes ragistomag, an earlier-stage candidate in phase 1 for solid tumors. On the ophthalmology side, NovaBridge is developing VIS-101, a bispecific biologic targeting VEGF-A and ANG-2 that has reached phase 2 evaluation for wet age-related macular degeneration and diabetic eye conditions.
The company generates revenue through strategic partnerships and licensing agreements rather than commercial drug sales at this stage. It collaborates with major pharmaceutical names including Bristol Myers Squibb on givastomig development, AskGene on VIS-101, and AbbVie on lemzoparlimab, an immunotherapy asset. Founded in 2014 and headquartered in Rockville, Maryland, NovaBridge (formerly known as I-Mab) operates…
Today's top-scoring strategy for NBP
Our engine ranks defined-risk strategies on the live NBP chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $2.5 | $0.65 |
| Sell | 1× | PUT | $2.5 | $0.65 |
| Sell | 1× | CALL | $2.5 | $0.18 |
| Buy | 1× | CALL | $5 | $0.05 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Strategy analysis
Greeks vs price
Price × volatility (today)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $2 | −$3 | −$8 | −$12 | −$16 | −$19 |
| $2 | $0 | −$4 | −$9 | −$13 | −$16 |
| $2 | $3 | −$1 | −$6 | −$10 | −$13 |
| $2 | $6 | $1 | −$3 | −$6 | −$10 |
| $2 | $7 | $4 | $0 | −$4 | −$7 |
| $2 | $9 | $6 | $2 | −$1 | −$4 |
| $2 | $10 | $8 | $5 | $2 | −$1 |
| $2 | $11 | $9 | $7 | $4 | $1 |
| $1 | $12 | $10 | $8 | $6 | $3 |
| $1 | $12 | $11 | $9 | $7 | $5 |
| $1 | $13 | $12 | $10 | $9 | $7 |
Live scan from 2026-07-28 · quotes delayed ~15 minutes
Historical backtest: how a Iron Butterfly on NBP would have performed
We approximated a Iron Butterfly on NBP, entered repeatedly over the past year (93 historical entries, each held to expiration) with Black-Scholes-modelled entry premiums. Here is how that would have played out on real NBP price history — an educational backtest, not a prediction of future returns.
Approximate: entry premiums are modelled with Black-Scholes from trailing realised volatility, held to expiration and settled against the real historical close. Real fills, implied volatility and slippage differ — treat it as directional context, not exact returns.
Implied volatility
NBP is currently trading with high implied volatility, which makes its options expensive — and attractive to sell. On the options we scanned that was around 177% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on NBP currently price in about 177% implied volatility, versus roughly 55% the stock has actually realised over the past month. That makes options relatively expensive — an edge for strategies that sell premium, such as credit spreads and iron condors.
Off that volatility, the options market is pricing a move of about ±$0.78 (±45%) in NBP by 2026-08-21 — a range of roughly $0.97 to $2.52. Strikes inside that band hold most of the premium and see most of the action.
NBP options chain highlights: open interest, volume and skew
The live NBP options chain shows a put/call open-interest ratio of 0.1 (bullish-leaning (more calls)), with at-the-money implied volatility near 128.1%.
Snapshot of open interest, volume and implied volatility for the nearest scanned expiration — context, not a trading signal.
NBP insider trading activity (SEC Form 4)
Open-market insider transactions at NBP over roughly the last six months, from SEC Form 4 filings. Open-market buys are the rarer, more telling signal — routine selling under pre-arranged plans is common, so read a net-selling figure with that in mind.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Xu Cong Claire | Sell | 4,485 | $4K | 2026-07-06 |
| Dennis Phillip Andrew | Sell | 8,494 | $6K | 2026-06-18 |
| Xu Cong Claire | Sell | 3,494 | $14K | 2026-06-01 |
| Cao Sean Wuxiong | Sell | 21,399 | $43K | 2026-05-14 |
| Hagler Mark Arnold | Buy | 230,000 | $577K | 2026-04-24 |
Source: SEC Form 4 filings via Finnhub. Open-market purchases (P) and sales (S) only — grants, option exercises, gifts and tax withholding are excluded. Informational context, not investment advice.
Earnings & IV crush
NBP's next earnings report is due around August 20, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
With earnings roughly 5 days out, NBP's 177% implied volatility is inflated by event premium — and it usually collapses the moment results drop ("IV crush"). That rewards defined-risk premium sellers when the move stays muted, and punishes option buyers who paid the inflated price. Keep size small and risk defined through the report.
Key figures
- Market cap
- $190M
- Beta (vs market)
- 1.48
- 52-week range
- $1.46–$6.79 (5% up the range)
- Short interest
- 6.3% of float · 5.5 days to cover
How to choose an options strategy for NBP
Start with your outlook on NBP, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while NBP stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open NBP in the free calculator →
Frequently asked questions
What is the best options strategy for NBP?
It depends on your outlook. Bullish traders often use a long call or bull call spread on NBP; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are NBP options liquid enough to trade?
NovaBridge Biosciences (NBP) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade NBP options?
Buying a single NBP call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade NBP or any security. Do your own research.
What does NovaBridge Biosciences do?
NovaBridge Biosciences (NBP) operates in the Biotechnology industry. The "About NovaBridge Biosciences" section above gives a fuller picture of what the company does and how it earns money.
Does NovaBridge Biosciences pay a dividend?
We don't show a confirmed dividend yield for NovaBridge Biosciences here, so treat it as uncertain: before writing calls, check its current dividend and ex-dividend date with your broker — an approaching ex-dividend date can trigger early assignment on in-the-money short calls.
When does NovaBridge Biosciences next report earnings?
NovaBridge Biosciences's next earnings are expected around August 20, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Tickers related to NBP
Comparing NBP with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 2440 Research Boulevard, Suite 400, Rockville, MD, 20850, United States
- Industry
- Biotechnology
- Employees
- 30
- CEO
- Dr. Srishti Gupta M.D.
- Phone
- 240 745 6330
- Website
- novabridge.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.